Feature | Published:

NIH inventions translate into drugs and biologics with high public health impact

Nature Biotechnology volume 32, pages 5258 (2014) | Download Citation

Compared with other US public-sector research institutions, the US National Institutes of Health has contributed inventions that have had a disproportionately greater impact on the overall number of products produced, drugs granted orphan status and drugs granted priority review.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , & Industry and the academy: uneasy partners in the cause of technological advance. in R. Noll (Ed.), Challenges to Research Universities, 171–200, Washington, DC: The Brookings Institution (1998).

  2. 2.

    Real effects of academic research. Am. Econ. Rev. 79, 957–970 (1989).

  3. 3.

    Academic research and industrial innovation. Res. Policy 20, 1–12 (1991).

  4. 4.

    , , & The economic impact of licensed commercialized inventions originating in university research. Res. Policy 42, 23–34 (2013).

  5. 5.

    et al. The licensing of DNA patents by US academic institutions: an empirical survey. Nat. Biotechnol. 24, 31–39 (2006).

  6. 6.

    , , & 30 years after Bayh-Dole: reassessing academic entrepreneurship. Res. Policy 40, 1045–1057 (2011).

  7. 7.

    & Incentives in university technology transfer. Int. J. Ind. Organ. 28, 362–367 (2009).

  8. 8.

    The Ewing Marion Kauffman Foundation. University Technology Transfer Through Entrepreneurship: Faculty and Students in Spinoffs. (2012).

  9. 9.

    Academic patents and access to medicines in developing countries. Am. J. Public Health 99, 9–17 (2009).

  10. 10.

    , & Private sector contributions to pharmaceutical science: thirty-five summary case histories. Am. J. Ther. 17, 101–120 (2010).

  11. 11.

    The importance of new companies for drug discovery: origins of a decade of new drugs. Nat. Rev. Drug Discov. 9, 867–882 (2010).

  12. 12.

    & What are the respective roles of the public and private sectors in pharmaceutical innovation? Health Aff. 30, 332–339 (2011).

  13. 13.

    , , , & The role of public sector research in the discovery of drugs and vaccines. N. Engl. J. Med. 364, 535–541 (2011).

  14. 14.

    Patent licensing under two policy frameworks: implications for patient access to diagnostic tests and licensing practice in the not for profit sector. BNA Life Sciences Law and Industry Report (23 March 2012).

  15. 15.

    An empirical review of major legislation affecting drug development: past experiences, effects and unintended consequences. Milbank Q. 89, 450–502 (2011).

  16. 16.

    , , & Financial anatomy of biomedical research. J. Am. Med. Assoc. 294, 1333–1342 (2005).

  17. 17.

    National Institutes of Health. NIH Intramural Research at the Threshold of a New Era. (2009).

  18. 18.

    National Institutes of Health Office of Technology Transfer. Fludara The New Benchmark: A Case Study. (2003).

  19. 19.

    et al. Financial anatomy of biomedical research 2003–2008. J. Am. Med. Assoc. 303, 137–143 (2010).

  20. 20.

    Abbott defends Norvir price hike. Chem. Eng. News 82, 6 (2004).

  21. 21.

    , , , , The cost of drug development: a systematic review. Health Policy. 100, 4–17 (2010).

  22. 22.

    , & Vaccines and Drugs: Characteristics of Their Use to Meet Public Health Goals. (2005).

  23. 23.

    National Institutes of Health. Actual Obligations by Institute and Center, FY 2000 - FY 2012 (2010).

Download references

Acknowledgements

We thank H. Feindt (NIH Office of Technology Transfer) for helpful insights on commercial sales of products, J. Duberman (Informationalist, NIH Library) for his assistance in gaining access to publications and sources of data, the NIH Office of Budget for NIH extramural funding data and L. Pressman for her valuable insights.

Author information

Affiliations

  1. Sabarni K. Chatterjee and Mark L. Rohrbaugh are at the Office of Technology Transfer, US National Institutes of Health, Rockville, Maryland, USA.

    • Sabarni K Chatterjee
    •  & Mark L Rohrbaugh

Authors

  1. Search for Sabarni K Chatterjee in:

  2. Search for Mark L Rohrbaugh in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Mark L Rohrbaugh.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.2785

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing